CRDF
$6.06
Cardiff Oncology
($.12)
(1.94%)
CRDF
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.17)
Revenue:  $0.03 Mil
Thursday
Nov 4
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRDF reports earnings?
Beat
Meet
Miss

Where is CRDF's stock price going from here?
Up
Flat
Down
Stock chart of CRDF
Analysts
Summary of analysts' recommendations for CRDF
Score
Grade
Pivots
Resistance
$6.41
$6.28
$6.17

$6.04

Support
$5.93
$5.80
$5.69
Tweet
Growth
Description
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.